Table 2.
Clone | Wild-type abl | Surface expression
|
|||
---|---|---|---|---|---|
CD43 | B220 | IgM | IgM−IL-7* | ||
AN-4a | − | + | + | − | − |
AN-4b | − | + | − | − | 4.7% |
AN-4c | − | + | + | − | − |
AP-4a | + | + | − | − | − |
AP-4b | + | + | + | − | 6% |
AN-5 | − | + | + | − | 3.1% |
AP-5 | + | + | − | − | 6.4% |
AN-6 | − | + | − | − | 3.6% |
AN-7 | − | + | − | − | − |
AP-8† | + | + | + | − | − |
IgM expression 3 days after IL-7 withdrawal.
Heterozygous for the mutant abl allele.